Every quarter, brand-name pharmaceutical manufacturers risk losing billions in revenue because a generic competitor files an Abbreviated New Drug Application […]
FDA Orange Book Monitoring: The Subscription Your Biopharma Clients Will Never Cancel Read Post »
There is a moment in every branded drug’s commercial life when a payer’s finance team opens a spreadsheet and starts
Every year, branded pharmaceutical manufacturers watch billions of dollars in revenue evaporate within months of a patent expiry. Generic filers
Patent cliffs kill revenue. Investors know it. What they often lack is a precise, well-sourced, actionable briefing that tells them
Own the Cliff: How Biopharma Data Providers Turn Patent Expiry Into Investor Revenue Read Post »
The global pharmaceutical industry is entering a period of wealth transfer that has no historical equivalent. Between 2025 and 2030,
Sell To Pharma Using Patent Timelines Read Post »
The $2 Billion Filing Error In March 2000, the USPTO denied a patent term extension application filed by Pfizer for
PTE Denied: The Rules That Kill Patent Term Extensions Before They Start Read Post »
The Name Behind the Molecule Every drug in clinical use has at least three names. There is the brand name,
The Drug Name Decoder: A Complete Guide to Generic Pharmaceutical Naming Read Post »
Section 1: The Strategic Calculus of a Paragraph IV Challenge The decision to initiate a Paragraph IV (Para IV) challenge
The pharmaceutical industry is entering a historic super-cycle of patent expirations between 2025 and 2030.1 During this window, an estimated
Sign in or create a free account to read this DrugPatentWatch article
